leisure time -WSS

leisure time

author：leisure time 2025-09-28 20:32:03 - browse：4

Adobe

LONDON — Merck said Wednesday it is buying ophthalmology-focused startup EyeBio in a deal worth up to $3 billion, as the pharma company looks to diversify its pipeline.

Under the deal, Merck, through a subsidiary, will pay $1.3 billion in cash upfront, with another $1.7 billion potentially included if certain regulatory and commercial milestones are met. The Wall Street Journal first reported the news Tuesday night.

EyeBio has been developing a drug called restoret for a number of retinal diseases, including age-related macular degeneration and diabetic macular edema. It presented data in February from a Phase 1/2 trial of restoret in both conditions. Merck said it plans to move restoret into a pivotal trial for diabetic macular edema later this year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： How to bring more disabled researchers into academia

WSS

How a billionaire couple greased the skids for Pelosi’s drug pricing bill

Anxious about a speech? A startup wants you to pop a minty cardiac drug

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Case highlights the risks of experimental stem cell therapy

Amylyx ALS drug failure raises questions and concerns

NEJM study link tiny plastics in blood vessels to heart problems

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Sen. Paul opposes bill to ban Chinese biotechs

Virginia high school admissions case could be legal follow

Headspace, Meta partner to launch VR meditation app for Quest

Guidelines to prevent youth baseball injuries need more muscle

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Heart attack and stroke risk calculators need revising

Helping hospitals and community health centers plan for resilience

Jerome Adams on the need for new antivirals for Covid

Helping hospitals and community health centers plan for resilience

explore

Air quality improving but still lags in Black, Hispanic communities

HIV vaccine remains elusive. Immunologists keep trying new ideas

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Data integrity in scientific journals requires "effort" by publishers, institutions

Wearables generate powerful data but its not useful to doctors, yet

hotspot

explore

hotspot

explore